MedTrace Logo

Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma

NCT06851221 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2025-02-28

No results posted yet for this study

Summary

This study on biological samples of patients affected by neuroblastoma and Ewing sarcoma aims at validating the beta3-adrenoreceptor as prognostic biomarker.

Conditions

Interventions

DIAGNOSTIC_TEST

beta3 expression

the samples leftover from the standard diagnostic procedures will be analyzed for the expression of the beta3-adrenoreceptor

Sponsors & Collaborators

  • Meyer Children's Hospital IRCCS

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
0 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-05
Primary Completion
2024-03-05
Completion
2024-03-05

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06851221 on ClinicalTrials.gov